Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • PB2512: SAFETY OF CRIZANLIZUMA...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS

Bibliographic Details
Published in:HemaSphere
Main Authors: Miguel Abboud, Julie Kanter, Kwaku Marfo, Charmaine Anthony, Jeremie Lincy, Michele Nassin, Vikas Joshi, Andreas Brueckner, Deborah Keefe, Kenneth I. Ataga
Format: Article
Language:English
Published: Wiley 2023-08-01
Online Access:http://journals.lww.com/10.1097/01.HS9.0000976748.46081.72
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000976748.46081.72

Similar Items

  • Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study
    by: Julie Kanter, et al.
    Published: (2024-11-01)
  • S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
    by: Matthew Heeney1, et al.
    Published: (2023-08-01)
  • Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran
    by: Marzieh Nosrati, et al.
    Published: (2025-08-01)
  • Proceedings of sessions of the Pirogov Surgical Societies № 2507–2512
    Published: (2018-10-01)
  • WCN24-2512 LUPUS PODOCYTOPATHY: CASE REPORT
    by: Alexandre Salvatore Pipino, et al.
    Published: (2024-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs